Cipla's Goa facility gets 2 USFDA Form 483 observations

Cipla Ltd announced that the USFDA conducted an inspection at its manufacturing facility in Verna, Goa, India, from April 6 to April 17, 2026. The inspection encompassed both routine current Good Manufacturing Practices (cGMP) and a Pre-Approval Inspection (PAI). Upon conclusion, the company received two (2) inspectional observations in Form 483. Cipla has stated its commitment to work closely with the USFDA and address these observations comprehensively within the stipulated timeframe. This is a standard regulatory process for pharmaceutical companies.